Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.

We have two exciting late-stage clinical assets and a range of earlier research programmes.

Our pipeline includes assets being developed from our own XF platform and two biotherapeutic products that harness specific components of the human microbiome.

Our lead asset, NTCD-M3, targets CDI. The company owns global rights to the world’s most advanced single strain, live bio-therapeutic product which is the non-toxigenic Clostridioides difficile strain M3 – for the prevention of recurring C. difficile gut infections (CDI). NTCD-M3 has already delivered world leading clinical efficacy data in a successful Phase 2 trial where the infection recurrence rate in NTCD-M3 treated patients was just 5%, compared to those on placebo where the infection recurrence rate was 30%. This product is preparing for Phase 3 clinical trials and could deliver peak sales of $0.5 billion.

XF-73 nasal is the lead asset from the company’s XF platform. It is a novel compound being developed for the prevention of post-surgical Staphylococcal infections. XF-73 reported very positive clinical data in 2021. The Phase 2b trial achieved its primary endpoint with >99% nasal bacterial load reduction (p<0.0001 versus placebo) achieved by the XF-73 nasal gel, with an excellent safety profile and no treatment related adverse events reported. Further information on the results of the trial can be found here. This product is preparing for Phase 3 clinical evaluation and approval and has a $1 billion sales forecast potential.

XF-73 (and other XF drugs from the platform) act via a novel, ultra-rapid action that kills targeted bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance.

The company is also developing a dermal formulation of XF-73 Dermal for the treatment of bacterial skin infections and has been supported by the US government’s National Institute for Allergy and Infectious Diseases, (part of the US National Institutes of Health). This product is in late-stage preclinical development.

Destiny Pharma is also collaborating with SporeGen on a novel SPOR-COV® innate immune system boosting treatment for the prevention of COVID-19 and similar respiratory viral infections using a Bacillus based approach. This project is at the preclinical development stage.